Role of ticlopidine on adriamycin-induced nephropathy.
The effect of ticlopidine on rats with adriamycin nephropathy was observed during 26 weeks. In the ticlopidine-treated nephrotic animals (TNG), proteinuria was less than in the untreated nephrotic animals (NG), but this difference was significant only at week 6 (TNG = 47.27 +/- 16.52 versus NG = 100.08 +/- 13.83 mg/24 h, p < 0.01) and week 26 (TNG = 157.00 +/- 28.73 versus NG = 217.00 +/- 21.73 mg/24 h, p < 0.01) after ADR injection. NG presented severe tubulointerstitial abnormalities with a tubulointerstitial lesion index of 3+. No difference in glomerular lesions was observed among the groups (NG median = 6%, TNG median = 4% and TCG median = 2%). The tubulointerstitial lesion index of TNG was less intense (median = 2+) but not different from those of the control groups (CG median = 1+; TCG median = 0+) nor NG (median = 3+). We concluded that the treatment with ticlopidine produced some partially beneficial effects but did not prevent the development of adriamycin-induced nephropathy.
Riyuzo
M C
MC
Departamento de Pediatria, Faculdade de Medicina, Universidade Estadual Paulista, Botucatu, SP, Brazil.
Soares
V A
VA
D000818:Animals; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D004353:Drug Evaluation, Preclinical; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011507:Proteinuria / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric; D013988:Ticlopidine / Q000627:therapeutic use*; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D010975:Platelet Aggregation Inhibitors; D004317:Doxorubicin; D013988:Ticlopidine